These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 23137576)

  • 21. Allopurinol: insights from studies of dose-response relationships.
    Day RO; Kannangara DR; Stocker SL; Carland JE; Williams KM; Graham GG
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):449-462. PubMed ID: 27927043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
    Dalbeth N; Stamp L
    Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N; Kumar S; Stamp L; Gow P
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How to select and use urate lowering agents for hyperuricemia].
    Yamanaka H
    Nihon Rinsho; 1996 Dec; 54(12):3261-5. PubMed ID: 8976102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
    Castrejon I; Toledano E; Rosario MP; Loza E; Pérez-Ruiz F; Carmona L
    Rheumatol Int; 2015 Jul; 35(7):1127-37. PubMed ID: 25519877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [How to treat hyperuricemia and gout attacks in compensated kidney failure?].
    Gröbner W
    Dtsch Med Wochenschr; 2002 Mar; 127(11):576. PubMed ID: 11894180
    [No Abstract]   [Full Text] [Related]  

  • 28. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The current state of care in gout: Addressing the need for better understanding of an ancient disease.
    Zychowicz ME; Pope RS; Graser E
    J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Febuxostat for prevention of gout attacks.
    Pohar S; Murphy G
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Febuxostat (Uloric) for chronic treatment of gout.
    Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hyperuricemia and gout: therapeutic indications].
    Pawlotsky Y
    Rev Prat; 1994 Jan; 44(2):206-9. PubMed ID: 8178077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing gout: how is it different in patients with chronic kidney disease?
    El-Zawawy H; Mandell BF
    Cleve Clin J Med; 2010 Dec; 77(12):919-28. PubMed ID: 21147946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Febuxostat versus allopurinol for gout.
    Gelber AC
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16602151
    [No Abstract]   [Full Text] [Related]  

  • 36. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
    Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M
    Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal arthropathies: recognizing and treating "the gouch".
    Quillen DM
    Prim Care; 2010 Dec; 37(4):703-11, v. PubMed ID: 21050952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy.
    Mu Z; Wang J; Wang W; Lv W; Chen Y; Wang F; Zhao Y; Dong B; Wang Y; Wang Z
    Int J Rheum Dis; 2020 Aug; 23(9):1145-1151. PubMed ID: 32483927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gout and hyperuricemia.
    Chilappa CS; Aronow WS; Shapiro D; Sperber K; Patel U; Ash JY
    Compr Ther; 2010; 36():3-13. PubMed ID: 21229813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.